79425-89-1

Usage

Type of compound

Heterocyclic aromatic compound

Structure

Naphthyridine ring with a thiol group attached at the 4th position

Organic synthesis

Building block for constructing more complex molecules

Pharmaceutical properties

Investigated for anti-inflammatory and antioxidant effects

Chemical reactivity

Thiol group makes it suitable for various chemical reactions and applications in medicinal chemistry and drug development

Additional studies

Potential use in materials science, particularly in the construction of supramolecular structures and functional nanomaterials

Upstream product

• 16795-72-5 4-oxo-1,4-dihydro-1,5-naphthyridine 
• 462-08-8 pyridin-3-ylamine 
• 5423-54-1 4-hydroxy-1,5-naphthyridine 
• 25063-68-7 2,2-dimethyl-5-[(pyridin-3-ylamino)methylidene]-1,3-dioxane-4,6-dione 
• 7689-63-6 4-chloro-1,5-naphthyridine 
• 79425-88-0 2-[1,5]Naphthyridin-4-yl-isothiourea; hydrochloride 

Downstream Products

• 79425-93-7 4-Benzylsulfanyl-[1,5]naphthyridine 
• 79425-95-9 4-Phenylmethanesulfonyl-[1,5]naphthyridine 

Relevant academic research and scientific papers

INHIBITORS OF RPN11

Candidate compounds for specific inhibition of Rpn11 are represented by Formula 1a where each of R2, R3, R4, R5, R6, and R7 is independently selected from hydrogen (H), substituted and unsubstituted alkyl groups, carboxyl groups, or substituted and unsubstituted carboxyamides.

Discovery of an Inhibitor of the Proteasome Subunit Rpn11

The proteasome plays a crucial role in degradation of normal proteins that happen to be constitutively or inducibly unstable, and in this capacity it plays a regulatory role. Additionally, it degrades abnormal/damaged/mutant/misfolded proteins, which serves a quality-control function. Inhibitors of the proteasome have been validated in the treatment of multiple myeloma, with several FDA-approved therapeutics. Rpn11 is a Zn2+-dependent metalloisopeptidase that hydrolyzes ubiquitin from tagged proteins that are trafficked to the proteasome for degradation. A fragment-based drug discovery (FBDD) approach was utilized to identify fragments with activity against Rpn11. Screening of a library of metal-binding pharmacophores (MBPs) revealed that 8-thioquinoline (8TQ, IC50 value ～2.5 μM) displayed strong inhibition of Rpn11. Further synthetic elaboration of 8TQ yielded a small molecule compound (35, IC50 value ～400 nM) that is a potent and selective inhibitor of Rpn11 that blocks proliferation of tumor cells in culture.

Discovery of potent and orally bioavailable inhibitors of Human Uric Acid Transporter 1 (hURAT1) and binding mode prediction using homology model

This Letter describes the discovery of a series of potent inhibitors of Human Uric Acid Transporter 1 (hURAT1). Lead generation and optimization via 3D pharmacophore analysis resulted in compound 41. With an IC50 of 33.7 nM, 41 also demonstrated good oral bioavailability in rat (74.8%) and displayed a consistent PK profile across all species tested (rat, dog and monkey).

SYNTHESIS AND PROPERTIES OF 4-SUBSTITUTED 1,5-NAPHTHYRIDINES AND THEIR N-OXIDES

4-Substituted 1,5-naphthyridines and their N-oxides were synthesized, and their structures and properties were studied.The IR and UV spectra of 4-hydroxy- and 4-methoxy-1,5-naphthyridines and their 1-oxides and 1-ethyl-4-oxo-1,4-dihydro-1,5-naphthyridine